Institute to be Directed by PacBio CSO Dr.
As part of the collaboration, a Single Molecule Real Time (SMRT™)
Biology User Facility will be established within the Institute.
Developed by Pacific Biosciences,
"The large-scale generation and integration of multiple sources of
biological data combined with clinical information will expand our
ability to characterize disease, and ultimately help develop and improve
the diagnosis and treatment of patients. This is the primary research
mission of
Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. His research has provided novel insights into what is needed to master diverse, large-scale data collected on normal and disease populations in order to elucidate the complexity of disease and make more informed decisions in the drug discovery arena. He has contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes and obesity, which have been widely published in leading scientific journals.
"The alliance between PacBio and Mount Sinai, and my dual role working with both organizations, will allow us to bring together the components required to catapult a new paradigm for clinical research and translational medicine," said Dr. Schadt. "Multiscale data integration, including genomic, expression, metabolite, protein, and clinical information, will ultimately define the future of patient care. With our intent to collaborate in areas such as newborn screening for rare genetic disorders, infectious diseases and cancer we hope to accelerate this revolution, starting by integrating clinical data with previously untapped biological information to build new computational models for predicting human disease."
Dr. Schadt is also a founding member of Sage Bionetworks, an open access
genomics initiative designed to build and support databases and an
accessible platform for creating innovative dynamic disease
models. Prior to joining Pacific Biosciences in 2009, he was Executive
Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of
The SMRT Biology User Facility at Mount Sinai will be equipped with
research and development versions of the PacBio SMRT technology
platforms. These systems, called Astros, have been used by Pacific
Biosciences and its collaborators to examine a number of important
biological processes including DNA sequencing, direct RNA sequencing,
protein translation and ligand binding. The
"With a strong commitment, shared vision, and extensive access to
patient samples, we believe Mount Sinai is a perfect partner to help
realize the promise of
For more information about
About
About Pacific Biosciences
Pacific Biosciences' mission is to transform the way humankind acquires,
processes and interprets data from living systems through the design,
development and commercialization of innovative tools for biological
research. The company has developed a novel approach to studying the
synthesis and regulation of DNA, RNA and proteins. Combining recent
advances in nanofabrication, biochemistry, molecular biology, surface
chemistry and optics, Pacific Biosciences has created a powerful
technology platform called single molecule, real-time, or SMRT™,
technology.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements may contain words such as "believe," "may," "estimate,"
"anticipate," "continue," "intend," "expect," "plan," the negative of
these terms, or other similar expressions, and include the assumptions
that underlie such statements. Such statements include, but are not
limited to, statements regarding the Company's
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6724091&lang=en
For
Ian.Michaels@mountsinai.org
or
For
Pacific Biosciences:
Media:
For
Pacific Biosciences
nicole@bioscribe.com
or
Investors:
Pacific
Biosciences
ir@pacificbiosciences.com
Source: Pacific Biosciences
News Provided by Acquire Media